AstraZeneca strengthens Lynparza push with prostate cancer data
September 30, 2019 at 10:30 AM EDT
AstraZeneca presented results on Monday for a trial of its Lynparza drug against prostate cancer, which it hopes could lead to wider regulatory approval for the treatment for use against more forms of the disease.